Stability of Eosinophilic Inflammation in COPD Bronchial Biopsies

DOI:

[10.1183/13993003.00622-2020](https://doi.org/10.1183/13993003.00622-2020)

Document Version

Accepted author manuscript

[Link to publication record in Manchester Research Explorer](#)

Citation for published version (APA):

Higham, A., Leow-Dyke, S., Jackson, N., & Singh, D. (2020). Stability of Eosinophilic Inflammation in COPD Bronchial Biopsies. *European Respiratory Journal*. <https://doi.org/10.1183/13993003.00622-2020>

Published in:

European Respiratory Journal

Citing this paper

Please note that where the full-text provided on Manchester Research Explorer is the Author Accepted Manuscript or Proof version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version.

General rights

Copyright and moral rights for the publications made accessible in the Research Explorer are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Takedown policy

If you believe that this document breaches copyright please refer to the University of Manchester's Takedown Procedures [<http://man.ac.uk/04Y6Bo>] or contact uml.scholarlycommunications@manchester.ac.uk providing relevant details, so we can investigate your claim.

Stability of Eosinophilic Inflammation in COPD Bronchial Biopsies

Andrew Higham¹, Sophie Leow-Dyke², Natalie Jackson² and Dave Singh^{1,2}

1. Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences,
Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The
University of Manchester and Manchester University NHS Foundation Trust, Manchester, UK.

2. Medicines Evaluation Unit, The Langley Building, Southmoor Road, Manchester, UK.

Corresponding Author:

Andrew Higham

Telephone: +44 161 291 4050

E-mail: Andrew.Higham@manchester.ac.uk

Manuscript word count = 1194

1 *To the editor:*

2 Blood eosinophil counts (BEC) predict the response to inhaled corticosteroids (ICS) in COPD
3 patients with increased exacerbation risk ^{1,2}. Studies have shown an association between BEC
4 and both sputum and lung tissue eosinophil counts in COPD patients ^{3,4}, supporting BEC as a
5 biomarker that reflects the degree of eosinophilic lung inflammation. While the long-term
6 stability of BEC in COPD patients has been studied ⁵⁻⁷, the stability of eosinophilic airway
7 inflammation in COPD patients is less clear. Good stability of COPD sputum eosinophil counts
8 up to 3 months has been reported ^{8,9}, but similar analysis using sub-mucosal eosinophil counts
9 (SMEC) are lacking.

10 We assessed COPD SMEC stability using samples from repeat bronchoscopies. We also
11 analysed SMEC variability using sections from the same bronchoscopy, and investigated the
12 relationship between BEC and SMEC.

13 Bronchial biopsies were obtained from 28 COPD patients; 14 had ≥ 2 bronchoscopies. The
14 inclusion criteria were; age >40 years, >10 pack-year smoking history, a post-bronchodilator
15 forced expiratory volume in 1 second (FEV₁) / forced vital capacity (FVC) ratio of <0.7 , and no
16 history of asthma. Bronchoscopies were performed at least 6 weeks after a respiratory
17 infection. Eight patients were female (29%), the mean age was 64 years, mean FEV₁ predicted
18 was 62%, 17 patients (61%) used ICS, 15 patients used LABA (54%), 9 patients used LAMA
19 (32%) and 17 patients were current smokers. The mean exacerbation frequency (an
20 exacerbation was defined as a COPD worsening that required a course of oral corticosteroids
21 and / or antibiotics, or caused hospitalisation) was 1.5 in the previous 12 months, and the
22 mean CAT score was 13. The mean bronchodilator reversibility was 214 ml (15%). All patients
23 were atopy negative and one patient had a rhinitis history. Blood immunoglobulin E

measurements were not available. This study was conducted in accordance with the amended Declaration of Helsinki. Local research ethics committees approved the study and patients provided written informed consent.

Bronchial biopsy analysis was conducted in three parts. Part 1 assessed intra-biopsy (within biopsy) SMEC variability. Part 2 assessed inter-biopsy (between biopsy) SMEC variability from the same bronchoscopy. Part 3 assessed intra-patient variability of SMEC over time from repeated bronchoscopies. Eosinophils were identified using the modified LUNA stain³. Blood eosinophil counts were collected where available (n=12).

Intraclass correlation coefficients (ICC) were calculated; these are interpreted as excellent (>0.75), fair to good (0.40 – 0.75) or poor (<0.40)¹⁰. Bland-Altman analysis examined the level of agreement (LOA) of SMEC between sections (part 1), between biopsies (part 2) and between visits (part 3). The mean difference and the LOA (mean difference plus or minus 1.96 X standard deviation (SD) of the difference, equivalent to z-score) were calculated. Spearman correlation was used to assess relationship between BEC and SMEC. P<0.05 was considered statistically significant.

Part 1: Up to 4 sections from 12 COPD patients (9 patients had 3 sections and 3 patients had 4 sections) were obtained; mean counts for sections 1 to 4 were 36.3, 34.0, 20.4 and 15.5 eosinophils/mm² respectively. The intra-patient standard deviation (SD) was 14.2 eosinophils/mm² and the ICC was 0.87.

Bland-Altman analysis demonstrated a mean difference of 13.0 and LOA -61.1 and 87.1 eosinophils/mm² (figure 1A). Visual inspection of the plot indicates greater mean differences at higher SMEC. To analyse this further, an arbitrary cut-off (20 eosinophils/mm²) was used to divide the cohort into eosinophil^{low} (mean difference 4.3; LOA -14.7 and 23.3

eosinophils/mm²) and eosinophil^{high} (mean difference 33.1 and wider LOA of -94.2 and 160.3 eosinophils/mm²) patients. The mean intra-patient SD of the eosinophil^{low} and eosinophil^{high} groups were 4.7 and 33.2 eosinophils/mm² respectively.

Part 2: Samples from 19 COPD patients were used; n=7 had 2 biopsies, n=10 had 3 biopsies and n=2 had 4 biopsies. The group mean counts for biopsies 1 to 4 were 22.2, 30.0, 17.9 and 52.1 eosinophils/mm² respectively. The mean intra-patient SD was 17.3 eosinophils/mm² and the ICC was 0.72.

Bland-Altman analysis showed a mean difference of 5.7 and LOA -61.8 and 73.3 eosinophils/mm². Variability was reduced in eosinophil^{low} patients (mean difference 3.3; LOA -22.9 and 29.5; SD 7.8; units = eosinophils/mm²) compared to eosinophil^{high} patients (mean difference 8.6; LOA of -89.1 and 106.2; SD 25.9; units = eosinophils/mm²). The precise location of each biopsy was not available.

Part 3: 14 COPD patients had repeat bronchoscopies, ranging from 1 month to 3 years apart (median 9 months; n=14 had 2 visits and n=6 had 3 visits). The group mean counts from visits 1 to 3 were 20.5, 41.0 and 63.4 eosinophils/mm² figure 1B). The mean intra-patient SD was 23.0 eosinophils/mm² and the ICC was 0.66.

Bland-Altman analysis showed a mean difference of 30.7 and LOA -85.8 and 147.2 eosinophils/mm² (figure 1C). Variability was reduced in eosinophil^{low} patients (mean difference 2.6; LOA -10.9 and 16.2; SD 4.3; units = eosinophils/mm²) compared to eosinophil^{high} patients (mean difference 51.6; LOA -94.7 and 197.9; SD 30.5; units = eosinophils/mm²).

1 Blood eosinophil counts were available for at least one of the visits for 12 out of the 14
2 patients (n=20 data points in total; median = 400 eosinophils/ μ L, n=2 were <100
3 eosinophils/ μ L, n=7 were between 100 – 300 eosinophils/ μ L, n=11 were >300
4 eosinophils/ μ L); blood and tissue eosinophil numbers were correlated (figure 1D R=0.7 and
5 p=0.001).

6 We assessed SMEC variability in COPD patients. ICC analysis demonstrated excellent
7 correlation (0.87) between results from the same biopsy (part 1), and good correlation (0.72)
8 between different biopsies from the same bronchoscopy (part 2) and repeated
9 bronchoscopies (0.66; part 3). In all 3 parts, Bland-Altman analysis demonstrated greater
10 variability in patients with higher SMEC. The results of parts 1,2 and 3 taken together indicate
11 that higher SMEC are associated with increased variation regionally (within the bronchial tree)
12 and over time, in contrast to lower SMEC counts which show less regional and temporal
13 variation.

14 Previous studies have reported associations between BEC and both sputum and lung
15 eosinophil counts ^{4 11}, although negative results have also been reported ¹². Our results show
16 a good correlation between SMEC and BEC, providing further evidence that BEC reflect the
17 extent of pulmonary eosinophilic inflammation in COPD patients.

18 COPD BEC studies have shown that lower BEC show good stability over time, with increased
19 variability at higher BEC ^{5 7}. We now show the same pattern for SMEC, while also
20 demonstrating an association between BEC and SMEC. Overall, these observations suggest
21 that the stability of BEC and SMEC behave in a similar manner. Inflammation involves dynamic
22 processes, including cell recruitment and activation; these BEC and SMEC observations
23 suggest that the presence of higher levels of eosinophilic airway inflammation (in the blood

and lungs) is prone to dynamic fluctuation over time. Furthermore, with reference to the use of BEC to predict the effects of ICS in COPD patients, our results support BEC as a biomarker which (i) reflect the degree of eosinophilic lung inflammation and (ii) shows a similar pattern of variation over time compared to SMEC.

In conclusion, the presence of lower levels of submucosal eosinophilic airway inflammation in COPD patients is relatively homogeneous throughout the bronchial tree and highly stable over time. In contrast, the presence of higher levels of eosinophilic airway inflammation is more heterogeneous throughout the bronchial tree, and shows increased biological variation over time.

Financial Support

This research was co-funded by the NIHR Manchester Biomedical Research Centre and the North West Lung Centre Charity, Manchester. This report is independent research and the views expressed in this publication are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

FIGURE LEGEND

Figure 1. Sub-mucosal eosinophil counts from COPD bronchial biopsies. (A) Bland-Altman analysis from part 1 shows the mean eosinophil count from section 1 vs section 2/3/4 from each patient plotted against the difference in eosinophil count of section 1 vs section 2/3/4 from each patient. Data plotted for all patients. The middle dashed line represents the mean difference of the data and the top and bottom dashed lines represent the limits of agreement. Vertical red line indicates threshold at 20 eosinophils/mm². (B) Eosinophil numbers were quantified from bronchial biopsies obtained during repeat bronchoscopies (part 3). Individual patients are presented (1 – 14) and each data point represents the mean count taken from two sections; different symbols (black circles and red triangles) are used alternately to enable clearer interpretation. The maximal difference between mean counts for each patient is represented at the top of the graph. (C) Bland-Altman analysis from part 3 shows the mean eosinophil count from bronchoscopy 1 vs bronchoscopy 2/3 from each patient is plotted against the difference in eosinophil count of bronchoscopy 1 vs bronchoscopy 2/3 from each patient. Data plotted for all patients. (D) Correlation between blood eosinophils and sub-mucosal eosinophils (n=20 data points).

1 REFERENCES

- 2 1. Singh D, Agusti A, Anzueto A, et al. Global Strategy for the Diagnosis, Management, and Prevention
3 of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. *Eur Respir J*
4 2019;53(5) doi: 10.1183/13993003.00164-2019
- 5 2. Bafadhel M, Peterson S, De Blas MA, et al. Predictors of exacerbation risk and response to
6 budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of
7 three randomised trials. *Lancet Respir Med* 2018;6(2):117-26. doi: 10.1016/S2213-
8 2600(18)30006-7
- 9 3. Kolsum U, Damera G, Pham TH, et al. Pulmonary inflammation in patients with chronic obstructive
10 pulmonary disease with higher blood eosinophil counts. *J Allergy Clin Immunol*
11 2017;140(4):1181-84 e7. doi: 10.1016/j.jaci.2017.04.027
- 12 4. Eltboli O, Mistry V, Barker B, et al. Relationship between blood and bronchial submucosal
13 eosinophilia and reticular basement membrane thickening in chronic obstructive pulmonary
14 disease. *Respirology* 2015;20(4):667-70. doi: 10.1111/resp.12475
- 15 5. Southworth T, Beech G, Foden P, et al. The reproducibility of COPD blood eosinophil counts. *Eur*
16 *Respir J* 2018;52(1) doi: 10.1183/13993003.00427-2018
- 17 6. Landis SH, Suruki R, Hilton E, et al. Stability of Blood Eosinophil Count in Patients with COPD in the
18 UK Clinical Practice Research Datalink. *COPD* 2017;14(4):382-88. doi:
19 10.1080/15412555.2017.1313827
- 20 7. Long GH, Southworth T, Kolsum U, et al. The stability of blood Eosinophils in chronic obstructive
21 pulmonary disease. *Respir Res* 2020;21(1):15. doi: 10.1186/s12931-020-1279-4
- 22 8. Boorsma M, Lutter R, van de Pol MA, et al. Repeatability of inflammatory parameters in induced
23 sputum of COPD patients. *COPD* 2007;4(4):321-9. doi: 10.1080/15412550701597720
- 24 9. Brightling CE, Monterio W, Green RH, et al. Induced sputum and other outcome measures in chronic
25 obstructive pulmonary disease: safety and repeatability. *Respir Med* 2001;95(12):999-1002.
26 doi: 10.1053/rmed.2001.1195
- 27 10. Koo TK, Li MY. A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for
28 Reliability Research. *J Chiropr Med* 2016;15(2):155-63. doi: 10.1016/j.jcm.2016.02.012
- 29 11. Kolsum U, Donaldson GC, Singh R, et al. Blood and sputum eosinophils in COPD; relationship with
30 bacterial load. *Respir Res* 2017;18(1):88. doi: 10.1186/s12931-017-0570-5
- 31 12. Turato G, Semenzato U, Bazzan E, et al. Blood Eosinophilia Neither Reflects Tissue Eosinophils nor
32 Worsens Clinical Outcomes in Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care*
33 *Med* 2018;197(9):1216-19. doi: 10.1164/rccm.201708-1684LE

(A)

(B)

(C)

(D)